In an “exceptional” emergency move, the FDA has greenlighted Remdesivir, an untested and experimental drug developed for the treatment of Ebola, to now be given to all hospitalized patients with advanced COVID-19 lung infections:
The results of US trials of antiviral drug remdesivir for treating coronavirus are encouraging, but it is too early to celebrate, the CEO of the drugmaker’s Israel branch said in an interview Monday.
The drug last week received fast-track FDA approval for emergency use in treating COVID-19.
. . . .
But recall how the FDA dragged its feet over even allowing the cheap, safe and effective hydroychloroquine to be tested on COVID-19 patients, despite overwhelming anecdotal evidence that it was actually curing many patients, not merely reducing their hospital stays by four days, as is the case with the expensive Remdesivir.
We reported in November of 2019, just a few months prior to the “pandemic” outbreak, that the FDA announced it was opening a satellite office in Tel Aviv to help fast-track Israeli drugs to the U.S. market.
Ukraine police expose Kyiv clinic trafficking babies